PL2968529T3 - Wytwarzanie formulacji orzeszków ziemnych do doustnego odczulania - Google Patents

Wytwarzanie formulacji orzeszków ziemnych do doustnego odczulania

Info

Publication number
PL2968529T3
PL2968529T3 PL14776121T PL14776121T PL2968529T3 PL 2968529 T3 PL2968529 T3 PL 2968529T3 PL 14776121 T PL14776121 T PL 14776121T PL 14776121 T PL14776121 T PL 14776121T PL 2968529 T3 PL2968529 T3 PL 2968529T3
Authority
PL
Poland
Prior art keywords
manufacture
oral desensitization
peanut
formulations
peanut formulations
Prior art date
Application number
PL14776121T
Other languages
English (en)
Inventor
Bryan Walser
Howard V. Raff
Original Assignee
Aimmune Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2968529(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aimmune Therapeutics, Inc. filed Critical Aimmune Therapeutics, Inc.
Publication of PL2968529T3 publication Critical patent/PL2968529T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Medical Informatics (AREA)
  • Pulmonology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
PL14776121T 2013-03-14 2014-03-12 Wytwarzanie formulacji orzeszków ziemnych do doustnego odczulania PL2968529T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784964P 2013-03-14 2013-03-14
EP14776121.7A EP2968529B1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization
PCT/US2014/024401 WO2014159607A1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization

Publications (1)

Publication Number Publication Date
PL2968529T3 true PL2968529T3 (pl) 2021-04-19

Family

ID=51528061

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14776121T PL2968529T3 (pl) 2013-03-14 2014-03-12 Wytwarzanie formulacji orzeszków ziemnych do doustnego odczulania

Country Status (18)

Country Link
US (5) US9198869B2 (pl)
EP (3) EP3482771B1 (pl)
JP (3) JP6752140B2 (pl)
CN (2) CN105101994B (pl)
AU (5) AU2014240404B2 (pl)
BR (1) BR112015021756B1 (pl)
CA (1) CA2903229A1 (pl)
DK (2) DK2968529T3 (pl)
ES (2) ES2940686T3 (pl)
FI (2) FI3482771T3 (pl)
FR (1) FR23C1026I1 (pl)
HK (1) HK1217660A1 (pl)
HU (1) HUE051831T2 (pl)
MX (1) MX2015010315A (pl)
PL (1) PL2968529T3 (pl)
PT (1) PT2968529T (pl)
SI (1) SI2968529T1 (pl)
WO (1) WO2014159607A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
US9198869B2 (en) 2013-03-14 2015-12-01 Aimmune Therapeutics, Inc. Manufacture of peanut formulations for oral desensitization
EP4275760A3 (en) 2014-08-25 2024-02-07 Société des Produits Nestlé S.A. Egg protein formulations and methods of manufacture thereof
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
SG11201706734SA (en) 2015-02-20 2017-09-28 Univ Leland Stanford Junior Mixed allergen compositions and methods for using the same
TW201709926A (zh) * 2015-04-23 2017-03-16 賽諾菲公司 用於舌下投藥之吡喃葡萄糖基脂a及過敏原調配物
US10856567B2 (en) 2016-07-22 2020-12-08 Kari Brown Baby food products containing allergenic proteins and methods of delivering same
US11439342B2 (en) * 2016-12-05 2022-09-13 Reacta Biotech Limited Oral food challenge meal formulations
SG10201913846XA (en) * 2017-01-13 2020-03-30 Aimmune Therapeutics Inc Methods of manufacture of nut flours and formulations for oral immunotherapy
BR102017026619A2 (pt) 2017-02-15 2018-10-30 Euroimmun Medizinische Labordiagnostika Ag ensaio melhorado para a diagnose de alergia a amendoim
SG11202000419QA (en) 2017-07-18 2020-02-27 Before Brands Inc Methods for making mixed allergen compositions
CA3080601A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy
GB201718342D0 (en) 2017-11-06 2017-12-20 Cambridge Allergy Ltd Allergenic protein formulations for immunotherapy
AU2019310602A1 (en) 2018-07-27 2021-02-04 Societe Des Produits Nestle S.A. Oral immunotherapy unit dose dispensing systems and methods
JP2022513974A (ja) * 2018-12-17 2022-02-09 アイミューン セラピューティクス,インコーポレイテッド 卵に対する経口免疫療法のための製剤、製造方法、及び卵アレルギーの治療
AU2019401214A1 (en) * 2018-12-20 2021-06-24 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
CN113507844A (zh) 2019-01-23 2021-10-15 前品牌股份有限公司 制备混合型过敏原组合物的方法
AU2020276213A1 (en) 2019-05-10 2021-10-28 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
CN114173764B (zh) * 2019-08-08 2024-02-06 赢创运营有限公司 固体剂型的制备方法和润滑剂
AU2020410909A1 (en) * 2019-12-23 2022-07-14 Prota Therapeutics Pty Ltd Pharmaceutical compositions
US20220220211A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
WO2023198674A1 (en) 2022-04-11 2023-10-19 Alk-Abelló A/S Peanut allergen composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) * 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
WO1992015285A1 (en) 1991-03-01 1992-09-17 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) * 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) * 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
WO2001040264A2 (en) 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Peptide antigens
EP1272213B1 (en) * 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
MXPA05009079A (es) * 2003-02-28 2006-05-19 Alk Abello As Forma de dosificacion que tiene una matriz de sacarido.
WO2005092360A1 (en) * 2004-03-19 2005-10-06 Xiu-Min Li Herbal therapy for the treatment of food allergy
WO2007075171A1 (en) 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
FR2924349B1 (fr) * 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
US20110288146A1 (en) 2008-11-19 2011-11-24 Nandu Deorkar Directly compressible granular microcrystalline cellulose based, excipient, manufacturing process and use thereof
BRPI0923377A2 (pt) 2008-12-19 2015-07-21 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) * 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081776A1 (es) * 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
CN101912364B (zh) * 2010-08-09 2015-07-15 刘会梅 银杏内酯b脂质体组合药物
GB201104537D0 (en) * 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
ES2936312T3 (es) * 2011-08-31 2023-03-16 Perosphere Tech Inc Métodos para la desensibilización eficaz y rápida de pacientes alérgicos
WO2013087119A1 (en) * 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
US9198869B2 (en) 2013-03-14 2015-12-01 Aimmune Therapeutics, Inc. Manufacture of peanut formulations for oral desensitization
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
EP4275760A3 (en) 2014-08-25 2024-02-07 Société des Produits Nestlé S.A. Egg protein formulations and methods of manufacture thereof
SG10201913846XA (en) 2017-01-13 2020-03-30 Aimmune Therapeutics Inc Methods of manufacture of nut flours and formulations for oral immunotherapy
CA3080601A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy

Also Published As

Publication number Publication date
US11141352B2 (en) 2021-10-12
JP7454519B2 (ja) 2024-03-22
EP2968529A4 (en) 2016-10-05
JP2016512537A (ja) 2016-04-28
FIC20230022I1 (fi) 2023-07-04
US20140271836A1 (en) 2014-09-18
HUE051831T2 (hu) 2021-03-29
DK2968529T3 (da) 2020-10-12
BR112015021756A8 (pt) 2019-11-19
BR112015021756A2 (pt) 2017-07-18
US20200129378A1 (en) 2020-04-30
US20160030289A1 (en) 2016-02-04
ES2826224T3 (es) 2021-05-17
ES2940686T3 (es) 2023-05-10
CN105101994A (zh) 2015-11-25
EP3998080A1 (en) 2022-05-18
CA2903229A1 (en) 2014-10-02
WO2014159607A1 (en) 2014-10-02
AU2020202685A1 (en) 2020-05-14
SI2968529T1 (sl) 2021-03-31
MX2015010315A (es) 2016-04-13
JP6891205B2 (ja) 2021-06-18
AU2020202685B2 (en) 2022-01-20
AU2016231523B2 (en) 2018-05-31
CN109125283A (zh) 2019-01-04
US20230120350A1 (en) 2023-04-20
AU2014240404A1 (en) 2015-09-17
AU2016231523A1 (en) 2016-10-06
DK3482771T3 (da) 2023-03-20
FR23C1026I1 (fr) 2023-10-06
JP2021073321A (ja) 2021-05-13
JP6752140B2 (ja) 2020-09-09
AU2022201858B2 (en) 2024-04-04
CN105101994B (zh) 2018-10-12
AU2014240404B2 (en) 2016-07-21
US20180042816A1 (en) 2018-02-15
JP2019108357A (ja) 2019-07-04
AU2022201858A1 (en) 2022-04-07
EP2968529B1 (en) 2020-08-05
BR112015021756B1 (pt) 2023-01-10
FI3482771T3 (fi) 2023-04-03
EP2968529A1 (en) 2016-01-20
EP3482771B1 (en) 2023-01-18
HK1217660A1 (zh) 2017-01-20
PT2968529T (pt) 2020-11-10
EP3482771A1 (en) 2019-05-15
US10449118B2 (en) 2019-10-22
US9198869B2 (en) 2015-12-01
AU2018222980A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
HK1217660A1 (zh) 用於口服脫敏的花生製劑的製備
HRP20190173T1 (hr) Oralne formulacije deferasiroksa
IL274024A (en) Oral preparations
IL245855A0 (en) Oral formulations of pyrrolidine derivatives
ZA201505830B (en) Formulations of organc compounds
PL2967110T3 (pl) Przekąski w postaci gumy do żucia oraz sposoby ich wytwarzania
HK1220125A1 (zh) 拉喹莫德的透皮配方
GB201305103D0 (en) An oral dosage form
HK1225301A1 (zh) 美他沙酮製劑
SG11201604136PA (en) Improved formulations for virosomes
TH1501001055A (th) ชิ้นสอดช่องปาก